YYC301 + celecoxib

YYC301 + celecoxib is a fixed-dose combination therapy under development for the treatment of chronic pain. YYC301 refers to a combination product that includes celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor nonsteroidal anti-inflammatory drug (NSAID), and tramadol, an opioid analgesic. Celecoxib works by selectively inhibiting COX-2, thereby reducing the production of prostaglandins involved in pain and inflammation. The addition of tramadol provides further analgesic effects through its action as a weak opioid receptor agonist and inhibitor of norepinephrine and serotonin reuptake. This combination aims to provide enhanced pain relief while potentially minimizing the dose-related side effects associated with each component when used alone[4][7][8].

Other names

celecoxib/tramadoltramadol/celecoxibcelecoxib-tramadol co-crystalCTC